Clopidogrel+acetylsalicylic acid — Competitive Intelligence Brief

Clopidogrel+acetylsalicylic acid (Clopidogrel+acetylsalicylic acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet agent. Area: Cardiovascular.

phase 3 Dual antiplatelet agent P2Y12 receptor (clopidogrel); cyclooxygenase (acetylsalicylic acid) Cardiovascular Small molecule

Target snapshot

Clopidogrel+acetylsalicylic acid (Clopidogrel+acetylsalicylic acid) — Rigshospitalet, Denmark. This combination inhibits platelet aggregation through two complementary pathways: clopidogrel blocks ADP-mediated platelet activation while acetylsalicylic acid inhibits thromboxane A2 synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clopidogrel+acetylsalicylic acid TARGET	Clopidogrel+acetylsalicylic acid	Rigshospitalet, Denmark	phase 3	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (acetylsalicylic acid)
Aspirin combined with clopidogrel	Aspirin combined with clopidogrel	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Dual antiplatelet agent	Cyclooxygenase (COX) and P2Y12 receptor
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Aspirin and clopidogrel/Ticagrelor	Aspirin and clopidogrel/Ticagrelor	Beijing Neurosurgical Institute	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor)
Clopidogrel with aspirin	Clopidogrel with aspirin	University of Florida	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
Aspirin and thienopyridine	Aspirin and thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Dual antiplatelet agent combination	COX-1 (aspirin); P2Y12 receptor (thienopyridine)
Aspirin + Ticagrelor	Aspirin + Ticagrelor	The First Affiliated Hospital with Nanjing Medical University	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (ticagrelor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet agent class)

1. Seoul National University Hospital · 3 drugs in this class
2. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
3. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
4. Inova Health Care Services · 1 drug in this class
5. Peking University Third Hospital · 1 drug in this class
6. Rigshospitalet, Denmark · 1 drug in this class
7. Texas Cardiac Arrhythmia Research Foundation · 1 drug in this class
8. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
9. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
10. University of Athens · 1 drug in this class